ZNF879: A Potential Drug Target and Biomarker (G345462)

Target Name: ZNF879

NCBI ID: G345462

ZNF879

ZNF879: A Potential Drug Target and Biomarker

Zinc finger proteins (ZFPs) are a family of non-coding RNAs that play a crucial role in various cellular processes. ZNF879, also known as Zinc finger protein 879, is a ZFP that is expressed in various tissues and has been shown to have various functions, including regulating gene expression, DNA replication, and cell signaling pathways. In recent years, ZNF879 has gained significant interest as a potential drug target and biomarker due to its unique biology and the involvement of several disease-related pathways.

The ZNF879 gene is located on chromosome 16 and encodes a protein that contains a zinc finger domain and several non-coding exons. The zinc finger domain is a common structural feature that consists of four conserved amino acids: arg-asp-glu-asp. This domain is known for its ability to interact with various molecules, including transcription factors, which allows ZNF879 to regulate gene expression.

Several studies have identified ZNF879 as a potential drug target due to its involvement in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. ZNF879 has been shown to play a role in several disease-related pathways, including cell signaling pathways, DNA replication, and gene expression regulation.

In cancer, ZNF879 has been shown to be involved in various signaling pathways, including the TGF-β pathway, which is a well-established pathway for cancer development. Several studies have shown that ZNF879 can be regulated by TGF-β and that its expression levels can be affected by various TGF-β inhibitors, such as anti-TGF-β antibodies or inhibitors. This suggests that ZNF879 may be a useful target for cancer therapies that target TGF-β signaling pathways.

In neurodegenerative diseases, ZNF879 has been shown to be involved in the development and progression of various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Several studies have shown that ZNF879 can be regulated by neurodegenerative diseases and that its expression levels can be affected by various neurodegenerative risk factors, such as inflammation, oxidative stress, and DNA damage. This suggests that ZNF879 may be a potential biomarker for neurodegenerative diseases and a target for therapies aimed at reducing the risk of these diseases.

In autoimmune disorders, ZNF879 has been shown to be involved in the development and regulation of autoimmune disorders. Several studies have shown that ZNF879 can be regulated by autoimmune disorders and that its expression levels can be affected by various autoimmune risk factors, such as genetic variation and environmental factors. This suggests that ZNF879 may be a potential biomarker for autoimmune disorders and a target for therapies aimed at reducing the risk of these disorders.

In conclusion, ZNF879 is a unique protein that has been shown to be involved in various cellular processes and has been identified as a potential drug target and biomarker. The zinc finger domain and its ability to interact with various molecules make ZNF879 an attractive target for small molecules, antibodies, or other therapeutic agents. Further research is needed to fully understand the role of ZNF879 in various diseases and to develop effective therapies aimed at targeting it.

Protein Name: Zinc Finger Protein 879

Functions: May be involved in transcriptional regulation

The "ZNF879 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF879 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets